Credit ACIP/CDC
#18,459
Amid growing concerns over the evolution and spread of the HPAI H5 virus, today the UK's Health Security Agency has announced that they have contracted with UK healthcare company CSL Seqirus to secure more than 5 million doses of an H5 influenza vaccine.
This follows similar moves by the EU, Japan, and the United States over the past 10 months:
HHS advances plan to produce 4.8 million H5N1 vaccine doses
None of these purchases is intended to protect an entire population, as it is expected to take 2 doses - 30 days apart - to convey immunity. With a population of nearly 70 million, the UK would need nearly 140 million doses while the United States would need over 600 million.
Since any pandemic strain would be expected to require a new, updated, vaccine in order to maximize its effectiveness, it doesn't make sense to order or manufacture huge quantities of vaccines based on older strains.
Having some quantity of pre-existing vaccine on hand, however, could allow certain high risk individuals (like farmers or HCWs) to be partially protected, while an updated vaccine is being developed.
Today's announcement does not provide a time-table for manufacture or delivery, but it generally takes several months to manufacture, fill and finish. The full statement from the UKHSA follows:
UK secures H5 influenza vaccine to boost pandemic preparedness
The purchase will boost the UK’s access to vaccines for a wider range of pathogens of pandemic potential.
From:UK Health Security Agency Published 3 December 2024
The UK Government has agreed a contract for more than five million doses of human H5 influenza vaccine to boost the country’s resilience in the event of a possible H5 influenza pandemic.
The vaccine, based on a current H5 avian influenza virus, will be manufactured by UK based healthcare company CSL Seqirus UK Limited.
The purchase has been made as part of long-established plans to boost the UK’s access to vaccines for a wider range of pathogens of pandemic potential.
Dr Meera Chand, Emerging Infection Lead at the UK Health Security Agency, said:
It is important for us to be prepared against a range of different influenza viruses that may pose human health risks. Early access to vaccines saves lives. Adding H5 vaccines to the interventions already available to us will help us to be ready for a wider range of threats.The influenza A(H5N1) virus has been causing a prolonged global outbreak, primarily in birds, over the past few years. It is only if this virus were to start spreading among humans, of which there is no evidence at this stage, that the human H5 influenza vaccine would be used.The procurement will strengthen the UK’s preparedness for a H5 influenza originated pandemic by ensuring that vaccines are immediately available, while a pandemic specific vaccine is made ready. The UK Government already has an advance purchase agreement for pandemic vaccines if or when they are needed, that would be tailored to combat the specific pandemic flu strain identified at the time.
Minister for Public Health and Prevention, Andrew Gwynne said:
Together with UKHSA, we are committed to ensuring that the UK is prepared and ready to respond to any current and future health threats.
Adding the H5 vaccine to our stockpile is one part of our preparedness plans, improving our readiness to respond to a range of emerging health threats and protecting people’s lives and livelihoods.
Marc Lacey, Global Head of Pandemic Preparedness and Response at CSL Seqirus, said:
As a global leader in outbreak and pandemic preparedness, CSL Seqirus is proud to partner with the UKHSA as part of its preparedness efforts against emerging influenza threats.
This agreement with the UK government demonstrates the ongoing importance of partnership in developing strong preparedness plans and ensuring rapid response capabilities against these health threats.
Dr Matt Chinn, Director of Scientific Operations at the Animal and Plant Health Agency (APHA), said:
APHA’s influenza teams have been at the forefront of the UK’s response to avian influenza viruses through sampling and testing both wild and farmed birds at the National Reference Laboratory for Avian Influenza at Weybridge.UKHSA actively monitors for human cases of avian influenza, while APHA targets surveillance at captive and wild birds and animals, through their robust surveillance programmes. This coupled with their genomic sequencing abilities are crucial to early detection, assessment and response to emerging health and biosecurity threats such as avian influenza.
This work is of vital importance in preparing and responding to emerging pathogen threats to the UK, helping us to contribute to a better understanding of the disease and offering reassurance to the public.
